Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study
Allergy2017Vol. 73(5), pp. 1003–1012
Citations Over TimeTop 20% of 2017 papers
Julia Eckl‐Dorna, Renate Fröschl, Christian Lupinek, Renáta Kiss, Pia Gattinger, Katharina Marth, Raffaela Campana, Irene Mittermann, K. Blatt, Peter Valent, Regina Selb, A Mayer, Katharina Gangl, Ilka Steiner, J. Gamper, Thomas Perkmann, Petra Zieglmayer, Philippe Gevaert, Rudolf Valenta, Verena Niederberger
Abstract
Intranasal administration of allergen induced rises of allergen-specific IgE levels, whereas intranasal administration of omalizumab did not enhance systemic total or allergen-specific IgE levels.
Related Papers
- → IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms(2022)51 cited
- → Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children(2014)42 cited
- → Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria(2020)11 cited
- → Kinetic Profiling of Clinical Symptoms and Basophil Parameters During Treatment of Chronic Spontaneous Urticaria with Omalizumab(2019)2 cited
- → Faculty Opinions recommendation of The Efficacy of Omalizumab Treatment in Chronic Spontaneous Urticaria is Associated with Basophil Phenotypes.(2021)